US 12,324,839 B2
Testosterone-inducing peptide compounds and associated combinations
Vassilios Papadopoulos, Pasadena, CA (US); and Daniel Benjamin Martinez-Arguelles, Ottawa (CA)
Assigned to ACESIS BIOMED US, INC., Centennial, CO (US)
Appl. No. 17/291,328
Filed by THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY, Montreal (CA)
PCT Filed Nov. 4, 2019, PCT No. PCT/CA2019/051559
§ 371(c)(1), (2) Date May 5, 2021,
PCT Pub. No. WO2020/093142, PCT Pub. Date May 14, 2020.
Claims priority of provisional application 62/756,767, filed on Nov. 7, 2018.
Prior Publication US 2022/0387606 A1, Dec. 8, 2022
Int. Cl. A61K 47/60 (2017.01); A61K 47/54 (2017.01); A61P 5/26 (2006.01)
CPC A61K 47/60 (2017.08) [A61K 47/542 (2017.08); A61P 5/26 (2018.01)] 20 Claims
 
1. An isolated peptide consisting of formula I:
 
 (I)
 
 A-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-
 
 
 
 Xaa6-Xaa7-Xaa8-B
wherein:
A is present or absent and is a moiety improving the circulation half-life of the isolated peptide;
Xaa1 is present or absent, when present Xaa1 is a L- or D-amino acid residue;
Xaa2 is present or absent, when present Xaa2 is a L-serine or D-serine;
Xaa3 is a L-lysine, a D-lysine, a L-arginine or a D-arginine;
Xaa4 is a L-valine, a D-valine, a L-isoleucine, a D-isoleucine, a L-leucine, a D-leucine, a glycine, a D-alanine or a L-alanine;
Xaa5 is a L-serine, a D-serine, a L-threonine or a D-threonine;
Xaa6 is a L-glutamine, a D-glutamine, a L-glutamic acid or a D-glutamic acid;
Xaa7 is present or absent, when present Xaa7 is a L-serine or a D-serine;
Xaa8 is present or absent, when present Xaa8 is a L- or D-amino acid residue; and
B is present or absent and is a moiety improving the circulation half-life of the isolated peptide, wherein A and B are not a peptide.